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Proteomic landscape 
of TGF‑β1‑induced fibrogenesis 
in renal fibroblasts
Shujun Zhou1, Xiaoke Yin2, Manuel Mayr2, Mazhar Noor1, Peter J. Hylands3 & Qihe Xu1*
Transforming growth factor‑β1 (TGF‑β1) plays a premier role in fibrosis. To understand the molecular 
events underpinning TGF‑β1‑induced fibrogenesis, we examined the proteomic profiling of a TGF‑
β1‑induced in vitro model of fibrosis in NRK‑49F normal rat kidney fibroblasts. Mass spectrometric 
analysis indicated that 628 cell‑lysate proteins enriched in 44 cellular component clusters, 24 
biological processes and 27 molecular functions were regulated by TGF‑β1. Cell‑lysate proteins 
regulated by TGF‑β1 were characterised by increased ribosomal proteins and dysregulated proteins 
involved in multiple metabolic pathways, including reduced Aldh3a1 and induced Enpp1 and Impdh2, 
which were validated by enzyme‑linked immunosorbent assays (ELISA). In conditioned media, 
62 proteins enriched in 20 cellular component clusters, 40 biological processes and 7 molecular 
functions were regulated by TGF‑β1. Secretomic analysis and ELISA uncovered dysregulated collagen 
degradation regulators (induced PAI‑1 and reduced Mmp3), collagen crosslinker (induced Plod2), 
signalling molecules (induced Ccn1, Ccn2 and Tsku, and reduced Ccn3) and chemokines (induced Ccl2 
and Ccl7) in the TGF‑β1 group. We conclude that TGF‑β1‑induced fibrogenesis in renal fibroblasts is an 
intracellular metabolic disorder and is inherently coupled with inflammation mediated by chemokines. 
Proteomic profiling established in this project may guide development of novel anti‑fibrotic therapies 
in a network pharmacology approach.
Transforming growth factor (TGF)-β activation of mesenchymal cells, e.g. fibroblasts, plays an important role 
in fibrosis, a pathological condition characterised by excessive accumulation of extracellular collagen  proteins1. 
Fibrosis affects virtually all organs, including the kidney, and causes chronic organ failure and  mortality2. For 
example, chronic kidney disease (CKD) affects 8–16% of the world’s  population3,4. CKD was the 12th most com-
mon cause of mortality and caused 4.6% of deaths globally in  20175. If this rising prevalence of CKD continues, 
it is predicted that CKD will become a top-5 cause of mortality worldwide by  20406. Given that kidney fibrosis is 
the common pathway mediating CKD progression to end-stage kidney disease, it has long been a burgeoning area 
of research investigating mechanisms of renal myofibroblasts-mediated fibrogenesis and related  intervention7.
To facilitate discovery of antifibrotics and mechanistic studies, we have used TGF-β1 to activate fibroblasts and 
other mesenchymal cells into myofibroblasts and to induce in vitro models of fibrosis suitable for high-through-
put  screening8. An in vitro model of fibrosis induced by TGF-β1 in NRK-49F normal rat kidney fibroblasts has 
been successfully used to examine antifibrotic and profibrotic activities, many of which have been recapitulated 
in animal studies and clinical  trials9–12. Thus, TGF-β1-induced fibrogenesis in NRK-49F cells offers a useful 
in vitro model for understanding the mechanisms of fibrosis, and for research and development of therapies for 
preventing and reversing renal fibrosis.
NRK-49F cells are arguably the most commonly used renal fibroblast clones in studies of renal fibrogenesis, 
and have been used in thousands of scientific reports ever since its first cloning and characterisation in  197813. 
It was among the earliest renal fibroblasts for studying cellular production and activation of latent TGF-β14,15 
and has been established as a suitable model to study TGF-β1-induced fibrogenesis in  199816. In this cellular 
model, many seminal discoveries have been made on TGF-β1-induced fibrogenesis in the past four decades, e.g. 
TGF-β1 dual regulation of fibroblast  proliferation17, mutually exclusive nature of TGF-β1-induced proliferation 
and fibrogenesis in  fibroblasts18, hepatocyte growth factor and Klotho antagonism to TGF-β119,20 and Smad and 
non-Smad signal transduction  pathways21–23.
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As far as we know, NRK-49F cells are the only renal fibroblasts in which TGF-β1-induced fibrogenesis has ever 
been studied by a proteomic  approach24. In 2009, Kang et al. conducted 2D-gel electrophoresis in-gel digestion, 
followed by matrix-assisted laser desorption/ionisation-time‐of‐flight mass spectrometry (MALDI-TOF–MS) 
analysis of selected spots differentially expressed in NRK-49F cells with and without TGF-β1 treatment for 6 h24. 
This study examined cell lysates only, identified 62 TGF-β1-regulated proteins and has established a proof of 
concept that a proteomics-based approach can be used to investigate mechanisms of fibrogenesis and potential 
antifibrotic  drugs24. However, this study has a few major limitations: (i) it did not examine conditioned media, 
which could provide crucial insights into fibrogenesis, a well-established disorder characterised by the accumu-
lation of collagen in the extracellular compartment; (ii) TGF-β1 treatment for 6 h was not sufficient to induce 
an established model of fibrosis and indeed, the authors did not show accumulation of total collagens in their 
samples for proteomic analysis; and (iii) 2D-gel electrophoresis detected more than 1500 protein spots, among 
which 150 were differentially displayed, but they only selected 78 for proteomic analysis. Thus, they failed to 
establish an un-biased complete proteomic view on TGF-β1-regulated  proteins24.
The objective of this study was to apply state-of-the-art proteomic technology to develop an unbiased systems 
view on intracellular and extracellular events underpinning TGF-β1-induced in vitro model of fibrosis in NRK-
49F cells and to identify novel intervening strategies.
Results
Establishment of TGF‑β1‑induced in vitro model of fibrosis. Quiescent NRK-49F cells were cul-
tured with 5 ng/ml TGF-β1 for 48 h to induce an in vitro model of fibrosis as we reported  before4–7. Cell lysates 
and conditioned media of TGF-β1 and control groups of four independent experiments were harvested for 
measurement of total collagen contents by hydroxyproline assay and soluble collagen assay, respectively. As 
shown in Fig. 1, TGF-β1 significantly induced total collagen in cell lysates and soluble collagen in conditioned 
media. The cell lysates and conditioned media were then trypsinised, labelled with tandem mass tag (TMT) 
reagents and subjected to high performance liquid chromatography (HPLC)-tandem mass spectrometry (MS/
MS) analysis.
Proteomic profiling and enzyme‑linked immunosorbent assays (ELISA) of cell lysates. HPLC–
MS/MS analysis identified 1438 proteins with at least 2 unique peptides detected and a 1% false discovery rate 
(FDR), among which 628 were regulated by TGF-β1 (p < 0.05, Supplementary table 1). Gene Ontology (GO) 
function enrichment analysis of TGF-β1-regulated proteins was performed on Database for Annotation, Visu-
alization and Integrated Discovery (DAVID; https ://david .ncifc rf.gov/). As shown in Fig. 2A, TGF-β1-regulated 
proteins were enriched in 44 GO cellular component clusters (p < 0.05, e.g. cytoplasm, extracellular exosome, 
nucleus, membrane, mitochondrion and cytosol categories), 24 GO biological process clusters (Fig.  2B, e.g. 
translation, oxidation–reduction process, response to drugs, cell–cell adhesion and fatty acid β-oxidation) and 
27 GO molecular function clusters (Fig. 2C, e.g. poly(A)RNA binding, protein binding, ATP binding, structural 
constituent of ribosome and protein homodimerisation).
KEGG analysis of TGF-β1-regulated proteins using DAVID unveiled 42 enriched pathways (Fig. 3), including 
14 pathways in which TGF-β1 repressed multiple proteins and 28 pathways in which TGF-β1 induced some and 
Figure 1.  TGF-β1-induced accumulation of total collagen in cell lysates and soluble collagen in conditioned 
media. NRK-49F cells were cultured with or without 5 ng/ml TGF-β1 for 48 h. Cell lysates and conditioned 
media were harvested for hydroxyproline assay (A) and soluble collagen assay (B) to quantify total and soluble 
collagens, respectively. Data of 4 independent experiments were normalised to the control group of each 
experiment and shown as mean ± SEM. ***p < 0.001 versus control group.
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Figure 2.  GO analysis of cell-lysate proteins regulated by TGF-β1. Numbers of involved proteins are indicated 
by the left y-axis and displayed as bars; p-values (as -Log10 values) are indicated by the right y-axis and 
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Figure 3.  KEGG pathway analyses of cell-lysate proteins regulated by TGF-β1. KEGG analysis of 628 cell-
lysate proteins regulated by TGF-β1 shows 42 pathways significantly regulated by TGF-β1. Y-axis represents 
significantly enriched KEGG pathway terms and X-axis indicates -Log10 p-value. KEGG pathway analysis of all 
proteins with TGF-β1/control ratios > 1.5 or < 0.67 is shown in the insert.
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repressed some other proteins. The proteins involved in each pathway are listed in Supplementary table 2. To 
focus on the top 20% proteins most robustly regulated by TGF-β1 in terms of fold-change, a cut-off of TGF-β1/
Control ratios > 1.5 (n = 51, accounting for 20.08% of all those 254 proteins induced by TGF β1) or < 0.67 (n = 76, 
accounting for 20.32% of 374 proteins repressed by TGF β1) was applied and the KEGG pathway analysis of 
short-listed proteins is also shown in Fig. 3, including 16 pathways in which multiple proteins were repressed by 
TGF-β1, 5 pathways in which TGF-β1 induced some and repressed some other proteins. Intriguingly, multiple 
proteins of the ribosome pathway were all induced by TGF-β1.
STRING analysis (https ://strin g-db.org/) of predicted direct (physical) and indirect (functional) associations 
among the 628 TGF-β1-regulated proteins created dense interaction networks that do not provide the resolu-
tion to see much details (not shown). Focusing on the interaction networks of proteins with TGF-β1/Control 
ratios > 1.5 or < 0.67, STRING analysis revealed two major clusters of proteins (highlighted as blue circle a and 
red circle b) connected by inosine-5′-monophosphate dehydrogenase 2 (Impdh2 in black square; Fig. 4A). The 
accession numbers, TGF-β1/Control ratios, p-values and q-values of proteins involved in clusters a and b are 
listed in Supplementary table 3, which showed that most proteins in cluster a, except Dpysl3, Slc7a1 and Slc7a5 
(located at periphery of the cluster), were down-regulated by TGF-β1, and that in cluster b, TGF-β1 up-regulated 
most proteins except Ak3, a mitochondrial enzyme located at the periphery of the cluster.
KEGG pathway analysis of proteins in these two clusters indicated that TGF-β1-induced in vitro model of 
fibrosis was mainly associated with multiple metabolic pathways (cluster a) and the ribosome pathway (cluster 
b) as highlighted in Fig. 4B. There were 18 pathways involved in cluster a and the top 3 with the lowest p-values 
were valine, leucine and isoleucine degradation, fatty acid degradation and metabolic pathways. As shown in 
Supplementary table 4, most proteins involved in metabolic pathways were down-regulated by TGF-β1. However, 
TGF-β1 significantly induced 10 ribosomal proteins, including four of the small subunit (Rps30, Rps24, Rps23 
and Rps3) and six of the large subunit (Rpl36a, Rpl35a, Rpl23a, Rpl37 Rpl27a and Rplp0). Thus, TGF-β1-induced 
fibrogenesis is associated with a previously unrecognised mismatch of reduced proteins involved in metabolic 
pathways and increased ribosomal proteins.
Volcano plot of all the 1438 identified proteins showed that Enpp1 and Aldh3a1 were the most robustly up- 
and down-regulated by TGF-β1, respectively (Fig. 5A). They were validated by ELISA (Fig. 5B,C). Also validated 
by ELISA was TGF-β1-induced Impdh2 (Fig. 5A,D), a middleman between two clusters of TGF-β1-regulated 
proteins (Fig. 4A).
Proteomic profiling and ELISA analysis of conditioned media. In total 725 proteins were identi-
fied in the conditioned media, of which 62 were regulated by TGF-β1 (p < 0.05), including 25 induced and 37 
repressed, respectively (Supplementary tables 5). TGF-β1-regulated proteins were enriched in 20 GO cellular 
component clusters (e.g. extracellular exosomes, cytoplasm, extracellular space, extracellular region, extracellu-
lar matrix; Fig. 6A & Supplementary table 6), 40 GO biological process clusters (e.g. cell adhesion, angiogenesis, 
proteolysis, cellular response to interleukin-1, positive regulation of ERK1 and ERK2 cascade; Fig. 6B & Sup-
plementary table 7) and 7 GO molecular functions associated with binding heparin, calcium ion, integrin, pro-
teoglycan, insulin-like growth factor, kininogen, CCR2 chemokine receptor (Fig. 6C & Supplementary table 8).
Upon STRING analysis, increased Serpine 1 (PAI-1), a potent inhibitor of collagen degradation, and repressed 
collagen-degradation enzyme Mmp3 centred the secretomic interaction map of TGF-β1-regulated proteins, sug-
gesting that TGF-β1 repression of collagen degradation might play a crucial role in TGF-β1-induced fibrogenesis. 
Also located at the centre of this secretomic interaction map were TGF-β1-induced chemokines Ccl2 (MCP-1) 
and Ccl7 (MCP-3), suggesting that TGF-β1-induced fibrogenesis may be inherently coupled with inflammation 
by promoting chemotactic effects (Fig. 7A).
KEGG pathway analysis suggested that TGF-β1 regulated the lysosome and the rheumatoid arthritis pathways 
in the conditioned media (Fig. 7B). Six proteins involved in the lysosome pathway (Gaa, Naga, Galns, Ctsl, Ctsb 
and Ap1b1) were all reduced in the TGF-β1 group. In the rheumatoid arthritis pathway, TGF-β1 induced Ccl2 
and suppressed Ctsl and Mmp3.
Volcano plot analysis was applied to display the 25 proteins induced by TGF-β1 and the 37 suppressed in 
conditioned media. As shown in Fig. 8A, PAI-1 was the most significantly and most dramatically induced by 
TGF-β1, accompanying up-regulation of chemokines Ccl2 and Ccl7, signalling mediators Cyr61 (Ccn1), Ctgf 
(Ccn2) and Tsku, and collagen crosslinking enzyme Plod2. In addition, TGF-β1 most dramatically repressed 
Nov (Ccn3) and suppressed collagen degradation enzyme Mmp3, among other proteins. These proteins were 
validated by ELISA (Fig. 8B–J).
Discussion
The proteomic technology has long been expected to be a powerful tool for unravelling the complex mechanisms 
of  fibrogenesis25. In this study, analyses of cell lysates and conditioned media of an in vitro model of TGF-β1-
induced fibrosis have led to complementary insights into the biological context of TGF-β1-induced fibrosis, 
characterised by dysregulated metabolism pathways, reduced Aldh3a1 and increased Enpp1 and Impdh2 in cells 
(Fig. 9A), and complex extracellular mechanisms regulating fibrogenesis and inflammation (Fig. 9B).
Our results show that TGF-β1-induced fibrogenesis may be an intracellular metabolic disorder characterised 
by increased intracellular ribosomal proteins and dysregulation of proteins involved in multiple other metabolic 
pathways (Figs. 3 and 4). To characterise the metabolite changes in conditioned-media and cell-lysate samples, 
we subjected them to metabonomic studies. Unfortunately, the results were inconclusive, at least in part, due to 
technical reasons. Nonetheless, our data clearly warrant further metabonomic studies of fibrogenesis and support 
intracellular metabolic pathways as novel antifibrotic  targets26.
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Figure 4.  TGF-β1 regulation of the ribosome pathway and many other metabolism pathways. (A) STRING 
analysis reveals predicted direct (physical) or indirect (functional) association among proteins regulated by 
TGF-β1/control ratios > 1.5 or < 0.67. (B) KEGG pathway analyses of proteins in clusters a and b. Cluster a 
contains proteins involved in multiple metabolic pathways; cluster b is enriched with proteins of the ribosome 
pathway only. In brackets, p-value and number of proteins involved are shown.
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TGF-β1 is well known to induce cell  hypertrophy27, which is associated with increased protein synthesis 
through regulating  mTOR28. mTORC1 positively regulates ribosomal RNA transcription, the synthesis of ribo-
somal proteins and other components required for ribosome  assembly29,30. Given roles for ribosomes in protein 
synthesis, it may not be surprising that the ribosome pathway is overwhelmingly induced by TGF-β1 (Fig. 3 and 
Supplementary table 2) and our results warrant further studies on roles for the ribosome pathway as a potential 
target for novel antifibrotic therapies.
Among proteins enriched in the glycine, serine and threonine metabolism pathway, Psph and Phgdh were 
induced by TGF-β1 (Supplementary table 2). Selvarajah et al. reported that TGF-β1 induced Psph and Phgdh in 
primary human lung fibroblasts in a Smad3- and mTORC1/ATF4-dependent manner and that interfering with 
the mTOR-ATF4 axis reduced Psph- and Phgdh-mediated serine and glycine biosynthesis from glucose, and 
Figure 5.  Volcano plot of cell-lysate proteins regulated by TGF-β1 and ELISA validation of TGF-β1 induction 
of Enpp1, Impdh2 and repression of Aldh3a1. Volcano plot (A); ELISA validation of Enpp1 (B), Aldh3a1 
(C) and Impdh2 (D). n = 4, ψψ: p < 0.01 versus control group. In Fig. 5A, red and green fonts highlight TGF-
β1-repressed and -induced proteins subjected to ELISA validation, respectively; red dots highlight proteins 
repressed by more than twofold; green dots highlight proteins induced by TGF-β1 more than twofold and 
Impdh2, which was selected for validation by ELISA although it was induced less than twofold.
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Figure 6.  GO analysis of proteins in conditioned media regulated by TGF-β1. Numbers of involved proteins 
are indicated by the left y-axis and displayed as bars; p-values (as -Log10 values) are indicated by the right y-axis 
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thus prevented the incorporation of glucose-derived glycine into collagen in TGF-β1 stimulated  fibroblasts31. 
TGF-β1-induced Psph and Phgdh were also enriched in carbon metabolism pathway, alongside TGF-β1-induced 
HK2 (Supplementary table 2). HK2 was the sole TGF-β1-induced protein enriched in glycolysis, gluconeogenesis, 
galactose, fructose and mannose metabolism pathways, among many other proteins repressed by TGF-β1 (Sup-
plementary table 2). HK2 is known to activate the Hippo pathway and mediate TGF-β1-induced fibrogenesis 
in murine and human lung fibroblasts and TGF-β-stimulated fibrogenesis can be repressed by pharmacological 
inhibition of HK2 in a mouse model of bleomycin-induced lung  fibrosis32. Among TGF-β-regulated proteins 
enriched in the starch and sucrose metabolism pathway, there were only two induced by TGF-β1, i.e. Enpp1 
and HK2. TGF-β1 more robustly induced Enpp1 than HK2 and, indeed, Enpp1 was the most robustly induced 
cell-lysate protein (Supplementary table 2; Fig. 5A,B). Enpp1 expression in vascular smooth muscle cells and end-
plate chondrocytes was TGF-β/Smad3-dependent33–35, although its exact role in TGF-β1-induced fibrogenesis 
remains obscure. It is plausible to hypothesise that, similar to HK-2, Enpp1, as an enzyme, may also mediate 
TGF-β1-induced fibrogenesis and thus be a novel antifibrotic target (Fig. 9A).
Another plausible target of TGF-β1-induced fibrosis is Impdh2, which links the ribosome and other metabo-
lism pathways (Figs. 4A, 5A,D) and is a known druggable target selectively repressed by Sappanone A, a plant-
derived small  molecule37. As rate-limiting enzymes mediating guanosine and deoxyguanosine biosynthesis, 
Figure 7.  STRING and KEGG pathway analyses of proteins in conditioned media regulated by TGF-β1. (A) 
STRING analysis of TGF-β1-regulated proteins in conditioned media revealed TGF-β1-induced PAI-1 and 
-repressed Mmp3 (red circle) and TGF-β1-induced chemokines Ccl2 and Ccl7 (blue circle) at the centre of 
the protein interaction network. (B) KEGG pathway enrichment analysis of TGF-β1-regulated proteins in 
conditioned media revealed only two pathways.
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Figure 8.  Volcano plot of TGF-β1-regulated secretome and ELISA validation of selected proteins in 
conditioned media. (A) Volcano plot; red and green fonts highlight TGF-β1-repressed and -induced proteins 
subjected to ELISA validation, respectively; red dots highlight proteins repressed by more than twofold and 
validated by ELISA; green dots highlight proteins induced by TGF-β1 more than twofold as well as Plod2 and 
Ctgf, which were selected for ELISA validation despite TGF-β1/Control ratios < 2. (B–J) ELISA, n = 4, ψψ, ψψψ: 
p < 0.01 and p < 0.001 versus control group.
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Impdh1 and Impdh2 are upstream of ribosome  biogenesis36. Non-selective Impdh1 and Impdh 2 inhibitors have 
multiple therapeutic values, including repressing  fibrosis38–40.
In contrast to TGF-β1-induced Psph, Phgdh, HK2 and Enpp1, all proteins involved in the tricarboxylic 
acid (TCA) cycle and a great majority of proteins involved in glycolysis/gluconeogenesis (except HK2) were 
reduced in TGF-β1 treated group (Fig. 3, Supplementary table 2). This suggests that TGF-β1-induced fibrogenesis 
is a consequence of metabolic maladaptation, characterised by switching TCA cycles off to give way to glycine 
and ribosome pathways. Indeed, Zhao et al. reported an overall decrease in TCA cycle metabolites and enzymes 
in lungs of patients with idiopathic pulmonary  fibrosis41. In a rat model of liver fibrosis, metabonomic analysis 
revealed reduced fumaric acid and increased succinic acid, indicating stagnated TCA  cycle42. The increased suc-
cinic acid may have crucial biological consequences in view that the metabolite has an emerging cytokine-like 
proinflammatory  effect43.
We found that multiple proteins involved in fatty acid degradation, metabolism and elongation were reduced 
in the TGF-β1 treated group (Fig. 3, Supplementary table 2). The role for fatty acid metabolism in TGF-β1-
induced fibrogenesis in fibroblasts is elusive, but its pro-fibrotic effects in renal tubular and endothelial cells are 
Figure 9.  Interpretation of findings of the study. Proteins with upright (induced by TGF-β1) and downwards 
(repressed by TGF-β1) arrows are validated by ELISA. (A) Main findings in cell-lysate proteins, characterised by 
reduced Aldh3a1, increased Enpp1 and Impdh2 and dysregulated metabolism pathways; (B) Main secretomic 
findings characterised by dysregulation of key matrix degradation regulators (PAI-1↑ and Mmp3 ↓), signalling 
mediators (Cyr61/Ccn1 ↑, Ctgf/Ccn2 ↑, Nov/Ccn3 ↓ and Tsku ↑) and a collagen crosslinker (Plod2 ↑), and 
induced chemokines (Ccl2 ↑ and Ccl7 ↑).
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now well  established44–46. Thus, targeting dysregulated fatty acid metabolism in TGF-β1-activated fibroblasts 
may also be a viable antifibrotic strategy.
Among TGF-β1-repressed intracellular proteins, Aldh3a1 and Cat (catalase) stand out (Fig. 5A,C). Catalase 
is a well-known scavenger of reactive oxygen species and its deficiency is known to promote renal  fibrosis47,48; 
Aldh3a1 is involved in multiple metabolic pathways, e.g. glycolysis/gluconeogenesis, β-alanine, histidine, phe-
nylalanine and tyrosine metabolism (Supplementary tables 2 and 4), and is implicated in ageing and response to 
hypoxia and cAMP (Supplementary table 6). Aldh3a1 is also protective against oxidative stress through multiple 
 mechanisms49–51, although the exact role for Aldh3a1 in TGF-β1-induced fibrogenesis in fibroblasts remains 
elusive and deserves further investigation (Fig. 9A).
Secretomic analysis suggests that lysosome and rheumatoid arthritis pathways were regulated by TGF-β1 
(Fig. 7B). TGF-β1 repression of the lysosome pathway may contribute to fibrogenesis and be a potential antifi-
brotic target, given that lysosomal enzymes may degrade collagens and the lysosome is a recognised potential 
therapeutic target in a variety of  diseases52. In the rheumatoid arthritis pathway, TGF-β1 induced Ccl2 and 
suppressed Ctsl and Mmp3. This may imply their involvement in regulating chronic inflammation as they do 
in rheumatoid arthritis.
As shown in Fig. 9B, TGF-β1-induced in vitro model of fibrosis in NRK-49F fibroblasts results from reduced 
collagen degradation, increased crosslinking and dysregulated pro-fibrotic and pro-inflammatory signals. PAI-1 
(Serpine1), the protein most robustly induced by TGF-β1 in the conditioned media, is a potent inhibitor of 
plasminogen activators, which mediate collagen  degradation53,54. PAI-1 is known to mediate kidney  fibrosis55,56 
and has been considered a potential target for antifibrotic  therapy57.
The matrix metalloproteinase (MMP) system also play a critical role in collagen  degradation58. We found 
that TGF-β1 reduced Mmp3 (Stromelysin), which is known to degrade collagen types II, III, IV, IX, and X, 
proteoglycans, fibronectin, laminin and  elastin59–61 and it also activates other MMPs such as MMP-1, MMP-7, 
and MMP-9, rendering MMP-3 crucial in degradation of collagen and other extracellular matrix  proteins62. We 
hypothesise that reduced Mmp3 in the conditioned media, together with increased PAI-1, would contribute to 
reduced collagen degradation and fibrogenesis. However, roles for Mmp3 might well be more complicated in 
view that Mmp-3 also has MMP activity-independent functions. For example, a novel transcription factor-like 
function of human MMP3 in regulating the pro-fibrotic Ctgf (CCN2) gene has been  reported63.
Collagen crosslinking plays an important role in  fibrosis64. Plod2 is responsible for the hydroxylation of 
lysine residues in collagen telopeptides and is essential for collagen pyridinoline cross-link  formation65,66 and 
irreversible accumulation of  collagen64,67. The exact role for TGF-β1-induced Plod2 in fibrosis remains elusive. 
We hypothesise that Plod2 is profibrotic and that targeting Plod2 may be a novel anti-fibrotic strategy.
Ctgf (Ccn2) is regarded as major profibrotic molecule downstream TGF-β1 and a therapeutic target in renal 
 fibrosis68–70. Two additional CCN family members, Cyr61 (Ccn1) and Nov (Ccn3) may also play important 
roles in fibrogenesis, although these roles are less well established. Kim et al. reported that Cyr61 accumulated 
in livers of patients with cirrhosis and in murine models of hepatic injury. It triggered cellular senescence in 
activated hepatic stellate cells and portal fibroblasts, thereby limiting fibrogenesis and promoting regression 
of experimental liver fibrosis, and indeed, pharmaceutical administration of Cyr61 accelerated regression of 
established  fibrosis71. These findings suggest that activation of the Cyr61-induced senescence pathway may 
hold therapeutic promise. Furthermore, Nov was reported to be a negative regulator of Ctgf both in vitro72 and 
in vivo73, with the capacity to limit collagen accumulation and ameliorate fibrosis. Taken together, our results 
suggest that simultaneously targeting multiple CCN family members may lead to better antifibrotic  strategies74.
Tsku is a member of the secreted small leucine-rich repeat proteoglycan family that interacts with signalling 
molecules such as TGF-β175 and was reported to inhibit myofibroblast differentiation by competing with endog-
enous TGF-β176,77. Thus, TGF-β1-induced Tsku may play an anti-fibrotic role and deserves further investigation.
TGF-β1-induced chemokines Ccl2 (MCP-1) and Ccl7 (MCP-3) may lead to chemotactic effects and recruit-
ment of inflammatory cells, which can in turn regulate fibrogenesis and disease progression. For example, dia-
betic kidneys of Ccl2-deficient mice or those treated with Ccl2 inhibitors had reduced macrophage infiltration, 
reduced myofibroblast accumulation and ameliorated renal  fibrosis78,79, suggesting that Ccl2-mediated mac-
rophage accumulation contributed to myofibroblast activation and renal fibrosis. Roles for Ccl7 in interstitial 
nephritis have been investigated in a mouse model of obstructive nephropathy. In Ccl7-deficient mice, an early 
(0–3 days) decrease of inflammatory infiltration was followed by a later (3–8 days) decrease in collagen accu-
mulation. 10–14 days after obstruction, Ccl7-deficient mice displayed increased tubulointerstitial fibrosis and 
reduced  inflammation80. Thus, targeting chemokines Ccl2 and Ccl7 may be effective in reducing inflammation, 
but effects on fibrosis may be more complicated.
Despite all the above interesting results, caution must be exercised in interpreting the findings of this study. 
First, proteomic methodology used in this study has its limitations. For example, collagen contents in cell lysates 
and conditioned media were both significantly increased in the TGF-β1-treated group (Fig. 1). Bioimaging analy-
sis of immunofluorescence assays of this in vitro model showed significantly increased collagen types I &  III11. 
However, neither collagen type I nor III was significantly altered in our proteomic data, likely because of post-
translational modification, e.g. hydroxylation, glycosylation and crosslinking, which make the modified peptides 
unrecognisable by the proteomic method used in this study, rendering quantification of these proteins unreliable. 
This problem also applies to kinases and Smad2/3, which are known to be regulated by  phosphorylation19–23 
and can only be solved by specific, targeted proteomic  analyses81–85. Nonetheless, among proteomic data of all 
collagens, Col5a1 was the only one significantly regulated by TGF-β1 in both cell lysates (TGF-β1/Control ratio 
0.82, p < 0.05) and conditioned media (TGF-β1/Control ratio 1.56, p < 0.05) (Supplementary tables 1, 5). These 
results await further validation and are potentially important, given that collagen type V was recently reported to 
reduce scar size by preventing over-expression and over-activation of  integrins86. Second, ELISA kits were quan-
titative, sensitive and commercially available, and thus chosen for validating protein expression. ELISA cannot 
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differentiate different proteoforms, functions of which may vary. Third, NRK-49F cells originally derived from a 
single cell clone from a rat  kidney13, thus it may only represent a particular subtype of heterogenous resident renal 
fibroblasts and may have drifted from its original phenotype in vivo. In addition, sex, strain, species differences 
must exist. Nonetheless, in view of the long-standing, worldwide use of NRK-49F cells, especially in studying 
 fibrogenesis8–24, we propose that TGF- β1-induced in vitro model of fibrosis in this cell line and its proteomic 
profiling can be a useful reference model for comparison in future studies in other systems in vitro and in vivo.
In conclusion, we have established an unbiased holistic view of an in vitro model of TGF-β1-induced fibrogen-
esis in NRK-49F cells. Integrating intracellular and extracellular mechanisms, this study has laid the foundation 
for developing innovative therapeutic strategies in a network pharmacology  approach87. Finally, data presented 
in this report are part of a set of experiments comprising seven groups (Supplementary Fig. 1)—in addition to 
the control and TGF-β1 groups reported here, there are five more groups treated by TGF-β1 in the presence of 
different antifibrotic agents, comparison of which with the TGF-β1 group has allowed for developing a proteomic 
roadmap to differentiating mechanisms of different antifibrotics. Analysis of the latter is available  online88,89 and 
will be reported elsewhere.
Materials and methods
Materials. Human platelet TGF-β1 (R&D Systems, Abingdon, UK) was reconstituted in sterile 4 mM hydro-
chloric acid (HCl; VWR International Ltd, Lutterworth, UK) and 0.1% bovine serum albumin (BSA; PAA Lab-
oratories GmbH, Pasching, Austria) that had been filter-sterilised through polyethersulfone membrane with 
0.2 μm pore size (Sigma-Aldrich, Gillingham, UK). A stock solution of 10 ng/μl TGF-β1 was stored at − 80 °C 
until use. A vial of MS-SAFE protease and phosphatase inhibitors (Sigma-Aldrich) was dissolved into 2  ml 
10 × RIPA lysis and extraction buffer (Sigma-Aldrich) and stored at − 20 °C as a stock solution. 1 × RIPA buffer 
was used to lyse cells and extract proteins. Bicinchoninic acid (BCA) protein assay (Thermo-Fisher Scientific, 
Paisley, UK) was used to measure protein concentration of cell lysates. Total collagen contents were measured 
indirectly through the measurement of hydroxyproline using the QuickZyme Total Collagen Assay (QuickZyme, 
Leiden, The Netherlands). Soluble collagens in conditioned media were colourimetrically detected by the Sircol 
soluble collagen assay (Biocolor Ltd., County Antrim, UK). Information of ELISA kits used in this study is listed 
in Supplementary table 9.
Cell culture and TGF‑β1 treatment. The NRK-49F cell line was purchased from the UK distributor of 
American Type Culture Collection, LGC Standards (Teddington, UK) and was confirmed as rat cells showing 
typical morphology of fibroblasts, positive for mesenchymal cell marker, negative for epithelial and endothe-
lial markers, and was free of mycoplasma contamination (Supplementary Fig.  2). The cells were maintained 
as recommended by the suppliers in Dulbecco’s Modified Eagle Medium (DMEM, Thermo-Fisher Scientific) 
supplemented with 5% foetal calf serum (FCS, Sigma-Aldrich), 100 IU/ml penicillin and 100 μg/ml strepto-
mycin (PAA Laboratories) and 2.5 μg/ml amphotericin B (Thermo-Fisher Scientific) at 37 °C and 5%  CO2. For 
experiments, NRK-49F cells were grown in 75  mm2 flasks, 2.0 × 106 per flask, in DMEM supplemented with 2.5% 
FCS and 2.5% Nu-serum replacement for 3 days. Media were changed to 1% FCS DMEM supplemented with 
1 × insulin-transferrin-selenium (ITS, Sigma-Aldrich) and the cells were cultured for four additional days. Cells 
were washed with serum free, phenol red-free DMEM (Thermo-Fisher Scientific) and changed to fresh phenol 
red-free DMEM and incubated at 37 °C for 30 min. This step was repeated once and the media were changed to 
serum-free, phenol red-free DMEM with and without 5 ng/ml TGF-β1 and the cells were cultured for 2 days to 
induce fibrogenesis.
Harvest and preparation of conditioned media and cell lysates. The conditioned media were col-
lected, mixed with MS-SAFE protease and phosphatase inhibitors (Sigma-Aldrich) and centrifuged at 500  g 
for 5 min at 4  °C to remove pellets of detached cells and large debris. Supernatants were collected and then 
centrifuged at 2500 g for 5 min at 4 °C to remove smaller debris. The final supernatants were stored at − 80 °C 
until  use90. To extract cell lysates, flasks were placed on ice and washed thrice with cold phosphate buffer solu-
tion (PBS). RIPA buffer with protease and phosphatase inhibitors (Sigma-Aldrich), 1.0 ml per flask, was added 
to cover cell monolayer, scraped and harvested, and centrifuged at full speed for 10 min to remove debris. The 
supernatants were harvested, protein concentrations determined, and stored at − 80 °C for further analysis as 
cell-lysate samples.
QuickZyme total collagen assay. The assay was modified based on the method described by Prockop 
and  Udenfriend91 and conducted as per the manufacturer’s instructions.
Sircol soluble collagen assay. The assay was a dye-binding method designed for the analysis of acid and 
pepsin-soluble collagens and conducted as per the manufacturer’s instructions.
Sample preparation for proteomic analysis. Conditioned media were first concentrated with Amicon 
Ultra-0.5 3kD centrifugal filtration devices (Merck Millipore, Watford, UK). The cell lysates and conditioned 
medium samples were denatured by adding 6 M urea/2 M thiourea and reduced with 10 mM dithiothreitol for 
1 h at 37 °C. 50 mM iodoacetamide was added for alkylation and the samples were briefly spun down and incu-
bated for 1 h in the dark. Protein contents were precipitated by adding pre-chilled (− 20 °C) acetone (8 × volume) 
overnight at − 20 °C. Samples were centrifuged at 14,000 g for 25 min at 4 °C and supernatants subsequently dis-
carded. The pellets were dried in a Speed Vac vacuum centrifuge (Thermo-Fisher Scientific) and re-suspended 
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in 0.1 M triethylammonium bicarbonate (TEAB, pH = 8.2), and followed by digestion with trypsin (enzyme: 
substrate ratio, 1:50) overnight at 37 °C. The digestion was stopped by acidification of samples with 1% trif-
luoroacetic acid (TFA) then the samples were loaded onto 96-well MACROSpin C18 plates (Harvard Apparatus, 
Cambourne, UK) for peptide clean-up. The plate was firstly activated using 200 μl methanol and centrifuged at 
1000 g for 1 min, followed by washing steps with 200 µl 80% acetonitrile (ACN), 0.1% TFA, and three equilibra-
tion steps using 200 µl 1% ACN, 0.1% TFA with centrifugation (1000 g for 1 min) after each step. Samples were 
loaded into the plate and centrifuged at 1500 g for 1 min; the flow-through was reloaded onto the plate a second 
time and centrifugation repeated. The plate was then washed three times with 200 µl 1% ACN, 0.1% TFA, then 
centrifuged at 1500 g for 1 min. Finally, the peptides were eluted with 170 µl 50% ACN, 0.1% TFA and centri-
fuged at 1500 g for 1 min; this step was repeated and the eluates were combined. Eluted peptides were dried in 
a Speed Vac vacuum centrifuge and resuspended in 0.1 M  TEAB92,93. Isobaric labelling of digested peptides was 
performed using 10-plex TMT reagents (Thermo-Fisher Scientific) according to the manufacturer’s instruction. 
TMT-labelled samples were mixed and peptides were cleaned-up as described above. Finally, the eluates were 
dried using Speed Vac vacuum centrifuge and resuspended in 2% ACN, 0.05%  TFA94.
HPLC–MS/MS analysis. HPLC–MS/MS was carried out on an HPLC (Dionex UltiMate 3000 RSLCnano) 
hyphenated with an Orbitrap Fusion Lumos Tribrid Mass Spectrometer (Thermo-Fisher Scientific). Samples 
were injected onto a trap column (Acclaim PepMap100 C18 Trap, 5 mm × 300 μm, 5 μm, 100 Å) at a flow rate 
of 25 μl/min for 3 min, using mobile phase A: 2% ACN, 0.1% formic acid (FA) in LC–MS grade water. The 
following nano-flow LC gradient was then used to separate the peptides at 0.3 μl/min: 0–10 min, 2–10% B; 
10–200 min, 10–30% B; 200–210 min, 30–40% B; 210–220 min, 99% B; 220–250 min, 2% B, B = 80% ACN, 0.1% 
FA in water. The EASY-Spray nano column (Acclaim PepMap100 C18, 50 cm × 75 μm, 2 μm, 100 Å) was set at 
45 °C and coupled to an EASY-Spray ion source. The MS spectra were collected from an Orbitrap mass analyser 
with full ion scan mode over the mass-to-change (m/z) range 350–1550 m/z. MS/MS were performed on the Top 
Speed method to fit as many  MS2 scan in 3 s cycle time using collision-induced dissociation (CID) fragmenta-
tion and collected in linear ion trap. For each  MS2 scan, SPS-MS3 method was used to acquire the TMT reporter 
ion signal using higher-energy collisional dissociation (HCD) fragmentation and collected from Orbitrap. Raw 
files were analysed using Proteome Discoverer 2.1 and Mascot 2.3.01 (Matrix Science, London, UK) with the 
following parameters: full MS mass tolerance was set at 10 ppm for precursor ions,  MS2 mass tolerance was set at 
0.8 Da for fragment ions; trypsin was used as enzyme and maximum 2 missed cleavage was allowed; TMT-label 
on N-terminal and lysine, carbamidomethylation of cysteine were set as fixed modifications and oxidation of 
methionine, proline, lysine as variable modifications. UniProt/Swiss-Prot rat database (2016_02, 7947 protein 
entries) was used. Proteins with high identification confidence and with at least two independent peptides were 
used for quantification. The reporter ion signal was used as quantitative value and normalised to total ion signal 
then scaled to pooled control channel. Final protein tables were exported for subsequent  analysis92,93.
ELISA. ELISA of conditioned media for PAI-1, Ctgf, Plod2, Ccl2, Ccl7, Cyr61, Tsku, Nov and Mmp3, and 
of cell lysates for Enpp1, Aldh3a1 and Impdh2 were conducted according to the manufactures’ instructions. 
Absorbance was determined using a micro-plate reader. Experiments were in triplicates.
Bioinformatics. For proteomic analysis, data were presented by fold-changes indicated by TGF-β1:Control 
ratios, p-value and q-values. Volcano plot (Prism 8.0, GraphPad, San Diego, CA) was used to illustrate the distri-
bution of quantified proteins according to p-value and TGF-β1:Control ratio. Database for Annotation, Visuali-
sation and Integrate Discovery (DAVID, https ://david .ncifc rf.gov/) was used to investigate the biological path-
ways in which the differentially expressed proteins may participate. The STRING database (https ://strin g-db.
org) was then used to build protein–protein interaction networks to further explore their functions. For compar-
isons of collagen contents and ELISA results, t-tests were used. p < 0.05 was regarded as statistically significant.
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